查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1405893

抗真菌药物市场规模、份额、趋势分析报告：2024-2030年按药物类别、适应症、剂型、配销通路管道、地区和细分市场预测

Antifungal Drugs Market Size, Share & Trends Analysis Report By Drug Class (Azoles, Polyenes), By Indication (Dermatophytosis, Aspergillosis), By Dosage Form, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格

抗真菌药物市场成长与趋势：

Grand View Research的最新报告显示，到2030年，全球抗真菌药物市场规模预计将达到205.2亿美元。

预计2024年至2030年该市场将以3.8%的复合年增长率扩张。全球真菌感染疾病日益流行是推动市场成长的关键因素。此外，近年来，由于免疫抑制剂和恶性物、假体装置和植入物以及广谱抗生素的使用增加，真菌感染的感染疾病率增加。

根据美国疾病管制与预防中心2017年发布的统计数据，全球每年新发隐球菌脑膜炎感染疾病近22万例，每年有18.1万人死亡。由于爱滋病毒/爱滋病的高流行，大多数死亡病例发生在撒哈拉以南非洲地区。这表明由于全球范围内真菌感染疾病的流行，存在对抗真菌药物的潜在需求。

许多国家的政府当局已下令在全国范围内实施封锁，以遏制 COVID-19 的传播。同样，世界各地的卫生系统也在努力维持供应链。供应链延误也影响了抗真菌药物的需求。全球老年人口的成长可能会推动对治疗机会性真菌感染疾病的抗真菌药物的需求，因为老年人更容易受到感染疾病和爱滋病毒和癌症等慢性病的影响。由于难以诊断且死亡率和发病率较高的真菌感染疾病不断增加，预计到 2030 年，抗真菌药物的需求将保持强劲。

抗真菌药物市场报告亮点

  • Azole类药物占市场主导地位，2023年销售份额达47.6%。这一优势得益于诺沙非、布芬、Diflucan和 Cresemba 等关键治疗药物的影响。
  • 由于免疫力缺乏患者的发生率增加和感染復发率高，念珠菌症在 2023 年占据了最大的市场占有率。
  • 预计曲菌症在预测期内将出现显着的复合年增长率。曲菌症是由一种称为曲菌症的真菌引起的感染疾病，通常会影响呼吸系统。
  • 2023年，口服药物剂型领导市场。这是因为某些抗真菌药物被设计为口服给药以确保适当的吸收。
  • 2023年，医院药局将引领市场。医院药局在确保即时获得关键药物方面发挥关键作用。医院药局提供门诊病人和住院服务，促进真菌感染疾病的无缝治疗。
  • 北美占据市场主导地位，2023 年占 40.9% 的份额。该地区的优势归因于其高度发展的医疗基础设施、负担能力和不断提高的意识。
  • 预计亚太地区在预测期内将显着成长。这是由于目标人口庞大、医疗机构开拓新兴市场以及主要市场参与者不断增加的投资。

目录

第一章调查方法与范围

第 2 章执行摘要

第三章抗真菌药物市场变数、趋势、范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场抑制因素分析
  • 抗真菌药物市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第四章抗真菌药物市场：药物类别的估计和趋势分析

  • 2023年及2030年药品类别市场占有率
  • 细分仪表板
  • 按药物类别分類的全球抗真菌药物市场展望
  • 2018年至2030年市场规模、预测与趋势分析如下
    • Azole
    • Echinocandins
    • 多烯
    • 烯丙胺
    • 其他的

第五章抗真菌药物市场：适应症估计与趋势分析

  • 2023年及2030年指示市场占有率
  • 细分仪表板
  • 按适应症分類的全球抗真菌药物市场展望
  • 2018年至2030年市场规模、预测与趋势分析如下
    • 皮肤丝状菌症
    • 曲菌症
    • 念珠菌症
    • 其他的

第六章抗真菌药物市场：剂型预估及趋势分析

  • 剂型市场占有率，2023 年和 2030 年
  • 细分仪表板
  • 按剂型分類的全球抗真菌药物市场展望
  • 2018年至2030年市场规模、预测与趋势分析如下
    • 口腔医学
    • 软膏
    • 粉末
    • 其他的

第七章抗真菌药物市场：配销通路估算及趋势分析

  • 2023 年及 2030 年配销通路市场占有率
  • 细分仪表板
  • 按配销通路分類的全球抗真菌药物市场展望
  • 2018年至2030年市场规模、预测与趋势分析如下
    • 医院药房
    • 零售药房
    • 其他的

第八章抗真菌药物市场：区域估计及趋势分析

  • 2023 年及 2030 年区域市场占有率分析
  • 区域市场仪表板
  • 全球区域市场概况
  • 2018-2030年市场规模及预测趋势分析：
  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麦
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东/非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第9章竞争形势

  • 主要市场参与企业的最新趋势和影响分析
  • 公司/竞争分类
  • 供应商形势
    • 主要经销商及通路伙伴名单
    • 主要客户
    • 2023 年主要企业股票分析
    • NOVARTIS AG
    • PFIZER, INC.
    • BAYER AG
    • SANOFI
    • MERCK &CO., INC.
    • F. GSK PLC
    • ABBOTT
    • GLENMARK
    • ASTELLAS PHARMA, INC.
    • SCYNEXIS INC.
Product Code: GVR-1-68038-293-8

Antifungal Drugs Market Growth & Trends:

The global antifungal drugs market size is expected to reach USD 20.52 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 3.8% from 2024 to 2030. The increasing incidence of fungal infections worldwide is the key factor stoking the growth of the market. In addition, the rise in the adoption of immunosuppressive and antineoplastic agents, prosthetic devices and grafts, and broad-spectrum antibiotics has resulted in an increased incidence of fungal infections in recent years.

According to statistics published by the Centers for Disease Control and Prevention in 2017, it has been estimated that every year, nearly 220,000 new individuals are affected by cryptococcal meningitis, which is a brain infection and has resulted in 181,000 deaths per year around the world. Most of the deaths were reported in sub-Saharan Africa, due to the high prevalence of HIV/AIDS. This indicates the potential demand for antifungal drugs due to the high prevalence of mycological infections around the globe.

The government authorities in many countries had ordered nationwide lockdowns in order to contain the spread of COVID-19. Similarly, health systems in a number of countries around the world were having trouble maintaining their supply chains. The slowness of the supply chain has also impacted the demand for antifungal medications. As aged people are more prone to infectious diseases and chronic conditions, including HIV and cancer, the rise in the geriatric population worldwide is likely to stir up the demand for antifungals to treat opportunistic fungal infections. The demand for fungistatic agents is estimated to remain strong through 2030 due to mounting cases of fungal infections that are difficult to diagnose, yielding high mortality and morbidity rates.

Antifungal Drugs Market Report Highlights:

  • The Azoles drug class segment dominated the market and accounted for a revenue share of 47.6% in 2023. This dominance is attributed to the influence of key therapeutic agents, including noxafil, vfend, diflucan, and cresemba.
  • The Candidiasis segment held the largest market share in 2023 due to rising incidence of the disease in immunocompromised patients and high rate of recurrent infections.
  • Aspergillosis is expected to register significant CAGR during the forecast period. Aspergillosis is an infection caused by mold called aspergillosis, which usually affects the respiratory system.
  • Oral drugs dosage form led the market in 2023. This is attributed to the fact that certain antifungal medications are designed for oral administration to ensure proper ingestion.
  • Hospital pharmacies led the market in 2023. Hospital pharmacies play a key role in ensuring immediate access to crucial medications. They serve both out-patient and in-patient services, facilitating the seamless treatment of fungal infections.
  • North America dominated the market and accounted for 40.9% share in 2023. This region dominance is attributed to the highly developed healthcare infrastructure, better affordability, and increasing awareness.
  • Asia Pacific is anticipated to witness significant growth during the forecast period. This is owing to the presence of large target population, developing healthcare facilities, and increase in investments by leading market players.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug Class
    • 1.2.2. Indication
    • 1.2.3. Dosage Form
    • 1.2.4. Distribution Channel
    • 1.2.5. Regional scope
    • 1.2.6. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Drug Class outlook
    • 2.2.2. Indication outlook
    • 2.2.3. Dosage Form outlook
    • 2.2.4. Distribution Channel outlook
    • 2.2.5. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Antifungal Drugs Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing Incidence Of Fungal Infections
      • 3.2.1.2. Increase In Awareness
      • 3.2.1.3. Rising R & D Pertaining To The Development Of Novel Drugs
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High Cost Associated With Mrd Testing
      • 3.2.2.2. Complex Regulatory Framework Associated With Mrd Testing
  • 3.3. Antifungal Drugs Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Antifungal Drugs Market: Drug Class Estimates & Trend Analysis

  • 4.1. Drug Class Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Antifungal Drugs Market by Drug Class Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Azoles
      • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Echinocandins
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Polyenes
      • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.4. Allylamines
      • 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.5. Others
      • 4.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Antifungal Drugs Market: Indication Estimates & Trend Analysis

  • 5.1. Indication Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Antifungal Drugs Market by Indication Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Dermatophytosis
      • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. Aspergillosis
      • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3. Candidiasis
      • 5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.4. Others
      • 5.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Antifungal Drugs Market: Dosage Form Estimates & Trend Analysis

  • 6.1. Dosage Form Market Share, 2023 & 2030
  • 6.2. Segment Dashboard
  • 6.3. Global Antifungal Drugs Market by Dosage Form Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 6.4.1. Oral Drugs
      • 6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Ointments
      • 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. Powders
      • 6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.4. Others
      • 6.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Antifungal Drugs Market: Distribution Channel Estimates & Trend Analysis

  • 7.1. Distribution Channel Market Share, 2023 & 2030
  • 7.2. Segment Dashboard
  • 7.3. Global Antifungal Drugs Market by Distribution Channel Outlook
  • 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 7.4.1. Hospital Pharmacies
      • 7.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.2. Retails Pharmacies
      • 7.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.3. Others
      • 7.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Antifungal Drugs Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2023 & 2030
  • 8.2. Regional Market Dashboard
  • 8.3. Global Regional Market Snapshot
  • 8.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 8.5. North America
    • 8.5.1. U.S.
      • 8.5.1.1. Key country dynamics
      • 8.5.1.2. Regulatory framework/ reimbursement structure
      • 8.5.1.3. Competitive scenario
      • 8.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.2. Canada
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Regulatory framework/ reimbursement structure
      • 8.5.2.3. Competitive scenario
      • 8.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6. Europe
    • 8.6.1. UK
      • 8.6.1.1. Key country dynamics
      • 8.6.1.2. Regulatory framework/ reimbursement structure
      • 8.6.1.3. Competitive scenario
      • 8.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.2. Germany
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Regulatory framework/ reimbursement structure
      • 8.6.2.3. Competitive scenario
      • 8.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.3. France
      • 8.6.3.1. Key country dynamics
      • 8.6.3.2. Regulatory framework/ reimbursement structure
      • 8.6.3.3. Competitive scenario
      • 8.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.4. Italy
      • 8.6.4.1. Key country dynamics
      • 8.6.4.2. Regulatory framework/ reimbursement structure
      • 8.6.4.3. Competitive scenario
      • 8.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.5. Spain
      • 8.6.5.1. Key country dynamics
      • 8.6.5.2. Regulatory framework/ reimbursement structure
      • 8.6.5.3. Competitive scenario
      • 8.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.6. Norway
      • 8.6.6.1. Key country dynamics
      • 8.6.6.2. Regulatory framework/ reimbursement structure
      • 8.6.6.3. Competitive scenario
      • 8.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.7. Sweden
      • 8.6.7.1. Key country dynamics
      • 8.6.7.2. Regulatory framework/ reimbursement structure
      • 8.6.7.3. Competitive scenario
      • 8.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.8. Denmark
      • 8.6.8.1. Key country dynamics
      • 8.6.8.2. Regulatory framework/ reimbursement structure
      • 8.6.8.3. Competitive scenario
      • 8.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7. Asia Pacific
    • 8.7.1. Japan
      • 8.7.1.1. Key country dynamics
      • 8.7.1.2. Regulatory framework/ reimbursement structure
      • 8.7.1.3. Competitive scenario
      • 8.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.2. China
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Regulatory framework/ reimbursement structure
      • 8.7.2.3. Competitive scenario
      • 8.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.3. India
      • 8.7.3.1. Key country dynamics
      • 8.7.3.2. Regulatory framework/ reimbursement structure
      • 8.7.3.3. Competitive scenario
      • 8.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.4. Australia
      • 8.7.4.1. Key country dynamics
      • 8.7.4.2. Regulatory framework/ reimbursement structure
      • 8.7.4.3. Competitive scenario
      • 8.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.5. South Korea
      • 8.7.5.1. Key country dynamics
      • 8.7.5.2. Regulatory framework/ reimbursement structure
      • 8.7.5.3. Competitive scenario
      • 8.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.6. Thailand
      • 8.7.6.1. Key country dynamics
      • 8.7.6.2. Regulatory framework/ reimbursement structure
      • 8.7.6.3. Competitive scenario
      • 8.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.8. Latin America
    • 8.8.1. Brazil
      • 8.8.1.1. Key country dynamics
      • 8.8.1.2. Regulatory framework/ reimbursement structure
      • 8.8.1.3. Competitive scenario
      • 8.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.8.2. Mexico
      • 8.8.2.1. Key country dynamics
      • 8.8.2.2. Regulatory framework/ reimbursement structure
      • 8.8.2.3. Competitive scenario
      • 8.8.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.8.3. Argentina
      • 8.8.3.1. Key country dynamics
      • 8.8.3.2. Regulatory framework/ reimbursement structure
      • 8.8.3.3. Competitive scenario
      • 8.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.9. MEA
    • 8.9.1. South Africa
      • 8.9.1.1. Key country dynamics
      • 8.9.1.2. Regulatory framework/ reimbursement structure
      • 8.9.1.3. Competitive scenario
      • 8.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.9.2. Saudi Arabia
      • 8.9.2.1. Key country dynamics
      • 8.9.2.2. Regulatory framework/ reimbursement structure
      • 8.9.2.3. Competitive scenario
      • 8.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.9.3. UAE
      • 8.9.3.1. Key country dynamics
      • 8.9.3.2. Regulatory framework/ reimbursement structure
      • 8.9.3.3. Competitive scenario
      • 8.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.9.4. Kuwait
      • 8.9.4.1. Key country dynamics
      • 8.9.4.2. Regulatory framework/ reimbursement structure
      • 8.9.4.3. Competitive scenario
      • 8.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 9.2. Company/Competition Categorization
  • 9.3. Vendor Landscape
    • 9.3.1. List of key distributors and channel partners
    • 9.3.2. Key customers
    • 9.3.3. Key company market share analysis, 2023
    • 9.3.4. NOVARTIS AG
      • 9.3.4.1. Company overview
      • 9.3.4.2. Financial performance
      • 9.3.4.3. Product benchmarking
      • 9.3.4.4. Strategic initiatives
    • 9.3.5. PFIZER, INC.
      • 9.3.5.1. Company overview
      • 9.3.5.2. Financial performance
      • 9.3.5.3. Product benchmarking
      • 9.3.5.4. Strategic initiatives
    • 9.3.6. BAYER AG
      • 9.3.6.1. Company overview
      • 9.3.6.2. Financial performance
      • 9.3.6.3. Product benchmarking
      • 9.3.6.4. Strategic initiatives
    • 9.3.7. SANOFI
      • 9.3.7.1. Company overview
      • 9.3.7.2. Financial performance
      • 9.3.7.3. Product benchmarking
      • 9.3.7.4. Strategic initiatives
    • 9.3.8. MERCK & CO., INC.
      • 9.3.8.1. Company overview
      • 9.3.8.2. Financial performance
      • 9.3.8.3. Product benchmarking
      • 9.3.8.4. Strategic initiatives
    • 9.3.9. F. GSK PLC
      • 9.3.9.1. Company overview
      • 9.3.9.2. Financial performance
      • 9.3.9.3. Product benchmarking
      • 9.3.9.4. Strategic initiatives
    • 9.3.10. ABBOTT
      • 9.3.10.1. Company overview
      • 9.3.10.2. Financial performance
      • 9.3.10.3. Product benchmarking
      • 9.3.10.4. Strategic initiatives
    • 9.3.11. GLENMARK
      • 9.3.11.1. Company overview
      • 9.3.11.2. Financial performance
      • 9.3.11.3. Product benchmarking
      • 9.3.11.4. Strategic initiatives
    • 9.3.12. ASTELLAS PHARMA, INC.
      • 9.3.12.1. Company overview
      • 9.3.12.2. Financial performance
      • 9.3.12.3. Product benchmarking
      • 9.3.12.4. Strategic initiatives
    • 9.3.13. SCYNEXIS INC.
      • 9.3.13.1. Company overview
      • 9.3.13.2. Financial performance
      • 9.3.13.3. Product benchmarking
      • 9.3.13.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America antifungal drugs market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 4 North America antifungal drugs market, by Indication, 2018 - 2030 (USD Million)
  • Table 5 North America antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
  • Table 6 North America antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 7 U.S. antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 8 U.S. antifungal drugs market, by Indication, 2018 - 2030 (USD Million)
  • Table 9 U.S. antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
  • Table 10 U.S. antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 11 Canada antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 12 Canada antifungal drugs market, by Indication, 2018 - 2030 (USD Million)
  • Table 13 Canada antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
  • Table 14 Canada antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 15 Europe antifungal drugs market, by region, 2018 - 2030 (USD Million)
  • Table 16 Europe antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 17 Europe antifungal drugs market, by Indication, 2018 - 2030 (USD Million)
  • Table 18 Europe antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
  • Table 19 Europe antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 20 Germany antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 21 Germany antifungal drugs market, by Indication, 2018 - 2030 (USD Million)
  • Table 22 Germany antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
  • Table 23 Germany antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 24 UK antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 25 UK antifungal drugs market, by Indication, 2018 - 2030 (USD Million)
  • Table 26 UK antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
  • Table 27 UK antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 28 France antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 29 France antifungal drugs market, by Indication, 2018 - 2030 (USD Million)
  • Table 30 France antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
  • Table 31 France antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 32 Italy antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 33 Italy antifungal drugs market, by Indication, 2018 - 2030 (USD Million)
  • Table 34 Italy antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
  • Table 35 Italy antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 36 Spain antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 37 Spain antifungal drugs market, by Indication, 2018 - 2030 (USD Million)
  • Table 38 Spain antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
  • Table 39 Spain antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 40 Denmark antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 41 Denmark antifungal drugs market, by Indication, 2018 - 2030 (USD Million)
  • Table 42 Denmark antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
  • Table 43 Denmark antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 44 Sweden antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 45 Sweden antifungal drugs market, by Indication, 2018 - 2030 (USD Million)
  • Table 46 Sweden antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
  • Table 47 Sweden antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 48 Norway antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 49 Norway antifungal drugs market, by Indication, 2018 - 2030 (USD Million)
  • Table 50 Norway antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
  • Table 51 Norway antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 52 Asia Pacific antifungal drugs market, by region, 2018 - 2030 (USD Million)
  • Table 53 Asia Pacific antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 54 Asia Pacific antifungal drugs market, by Indication, 2018 - 2030 (USD Million)
  • Table 55 Asia Pacific antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
  • Table 56 Asia Pacific antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 57 China antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 58 China antifungal drugs market, by Indication, 2018 - 2030 (USD Million)
  • Table 59 China antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
  • Table 60 China antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 61 Japan antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 62 Japan antifungal drugs market, by Indication, 2018 - 2030 (USD Million)
  • Table 63 Japan antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
  • Table 64 Japan antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 65 India antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 66 India antifungal drugs market, by Indication, 2018 - 2030 (USD Million)
  • Table 67 India antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
  • Table 68 India antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 69 South Korea antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 70 South Korea antifungal drugs market, by Indication, 2018 - 2030 (USD Million)
  • Table 71 South Korea antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
  • Table 72 South Korea antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 73 Australia antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 74 Australia antifungal drugs market, by Indication, 2018 - 2030 (USD Million)
  • Table 75 Australia antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
  • Table 76 Australia antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 77 Thailand antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 78 Thailand antifungal drugs market, by Indication, 2018 - 2030 (USD Million)
  • Table 79 Thailand antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
  • Table 80 Thailand antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 81 Latin America antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 82 Latin America antifungal drugs market, by Indication, 2018 - 2030 (USD Million)
  • Table 83 Latin America antifungal drugs market, by application, 2018 - 2030 (USD Million)
  • Table 84 Latin America antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
  • Table 85 Latin America antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 86 Brazil antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 87 Brazil antifungal drugs market, by Indication, 2018 - 2030 (USD Million)
  • Table 88 Brazil antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
  • Table 89 Brazil antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 90 Mexico antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 91 Mexico antifungal drugs market, by Indication, 2018 - 2030 (USD Million)
  • Table 92 Mexico antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
  • Table 93 Mexico antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 94 Argentina antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 95 Argentina antifungal drugs market, by Indication, 2018 - 2030 (USD Million)
  • Table 96 Argentina antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
  • Table 97 Argentina antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 98 MEA antifungal drugs market, by region, 2018 - 2030 (USD Million)
  • Table 99 MEA antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 100 MEA antifungal drugs market, by Indication, 2018 - 2030 (USD Million)
  • Table 101 MEA antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
  • Table 102 MEA antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 103 South Africa antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 104 South Africa antifungal drugs market, by Indication, 2018 - 2030 (USD Million)
  • Table 105 South Africa antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
  • Table 106 South Africa antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 107 Saudi Arabia antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 108 Saudi Arabia antifungal drugs market, by Indication, 2018 - 2030 (USD Million)
  • Table 109 Saudi Arabia antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
  • Table 110 Saudi Arabia antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 111 UAE antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 112 UAE antifungal drugs market, by Indication, 2018 - 2030 (USD Million)
  • Table 113 UAE antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
  • Table 114 UAE antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 115 Kuwait antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 116 Kuwait antifungal drugs market, by Indication, 2018 - 2030 (USD Million)
  • Table 117 Kuwait antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
  • Table 118 Kuwait antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Antifungal drugs market: market outlook
  • Fig. 14 Antifungal drugs competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Antifungal drugs market driver impact
  • Fig. 20 Antifungal drugs market restraint impact
  • Fig. 21 Antifungal drugs market strategic initiatives analysis
  • Fig. 22 Antifungal drugs market: Drug Class movement analysis
  • Fig. 23 Antifungal drugs market: Drug Class outlook and key takeaways
  • Fig. 24 Azoles market estimates and forecast, 2018 - 2030
  • Fig. 25 Echinocandins market estimates and forecast, 2018 - 2030
  • Fig. 26 Polyenes market estimates and forecast, 2018 - 2030
  • Fig. 27 Allylamines market estimates and forecast, 2018 - 2030
  • Fig. 28 Others market estimates and forecast, 2018 - 2030
  • Fig. 29 Antifungal drugs market: Indication movement Analysis
  • Fig. 30 Antifungal drugs market: Indication outlook and key takeaways
  • Fig. 31 Dermatophytosis market estimates and forecasts, 2018 - 2030
  • Fig. 32 Aspergillosis market estimates and forecasts,2018 - 2030
  • Fig. 33 Candidiasis market estimates and forecasts, 2018 - 2030
  • Fig. 34 Others market estimates and forecasts,2018 - 2030
  • Fig. 35 Antifungal drugs market: Dosage form movement Analysis
  • Fig. 36 Antifungal drugs market: Dosage form outlook and key takeaways
  • Fig. 37 Oral drugs market estimates and forecasts, 2018 - 2030
  • Fig. 38 Ointments market estimates and forecasts,2018 - 2030
  • Fig. 39 Powders market estimates and forecasts, 2018 - 2030
  • Fig. 40 Others market estimates and forecasts,2018 - 2030
  • Fig. 41 Antifungal drugs market: Distribution channel movement Analysis
  • Fig. 42 Antifungal drugs market: Distribution channel outlook and key takeaways
  • Fig. 43 Hospital pharmacies market estimates and forecasts, 2018 - 2030
  • Fig. 44 Retail pharmacies market estimates and forecasts,2018 - 2030
  • Fig. 45 Others market estimates and forecasts,2018 - 2030
  • Fig. 46 Global antifungal drugs market: Regional movement analysis
  • Fig. 47 Global antifungal drugs market: Regional outlook and key takeaways
  • Fig. 48 Global antifungal drugs market share and leading players
  • Fig. 49 North America market share and leading players
  • Fig. 50 Europe market share and leading players
  • Fig. 51 Asia Pacific market share and leading players
  • Fig. 52 Latin America market share and leading players
  • Fig. 53 Middle East & Africa market share and leading players
  • Fig. 54 North America: SWOT
  • Fig. 55 Europe SWOT
  • Fig. 56 Asia Pacific SWOT
  • Fig. 57 Latin America SWOT
  • Fig. 58 MEA SWOT
  • Fig. 59 North America, by country
  • Fig. 60 North America
  • Fig. 61 North America market estimates and forecasts, 2018 - 2030
  • Fig. 62 U.S.
  • Fig. 63 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 64 Canada
  • Fig. 65 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 66 Europe
  • Fig. 67 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 68 UK
  • Fig. 69 UK market estimates and forecasts, 2018 - 2030
  • Fig. 70 Germany
  • Fig. 71 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 72 France
  • Fig. 73 France market estimates and forecasts, 2018 - 2030
  • Fig. 74 Italy
  • Fig. 75 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 76 Spain
  • Fig. 77 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 78 Denmark
  • Fig. 79 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 80 Sweden
  • Fig. 81 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 82 Norway
  • Fig. 83 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 84 Asia Pacific
  • Fig. 85 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 86 China
  • Fig. 87 China market estimates and forecasts, 2018 - 2030
  • Fig. 88 Japan
  • Fig. 89 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 90 India
  • Fig. 91 India market estimates and forecasts, 2018 - 2030
  • Fig. 92 Thailand
  • Fig. 93 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 94 South Korea
  • Fig. 95 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 96 Australia
  • Fig. 97 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 98 Latin America
  • Fig. 99 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 100 Brazil
  • Fig. 101 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 102 Mexico
  • Fig. 103 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 104 Argentina
  • Fig. 105 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 106 Middle East and Africa
  • Fig. 107 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 108 South Africa
  • Fig. 109 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 110 Saudi Arabia
  • Fig. 111 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 112 UAE
  • Fig. 113 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 114 Kuwait
  • Fig. 115 Kuwait market estimates and forecasts, 2018 - 2030
  • Fig. 116 Market share of key market players- Antifungal drugs market